New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

June 2017

Welcome to the June 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the June issue!

The PharmSource Team


Venture Capital Funding Confirms Transition to Large Molecule Assets

by Saul Richmond, Director of Market Intelligence

As the major source of funding for early stage companies, the Venture Capital (VC) sector can be viewed as a window into tomorrow’s therapies. Although absolute VC spend on Research and Development (R&D) is dwarfed by that of the Global Pharmaceutical sector, the overall importance of early stage funding is critical for a number of reasons:

a. Research and Development outlays constitute a significant proportion of overall VC funding (likely around 70%);

b. The early stage sector outsources most of its… read on

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type May 2017 YTD 2017
Early Development 102 536
Late Development 109 533
Biologic 100 509
Small Molecule 245 1208
Parenteral 105 554
Oral 96 460
New Financings 84 413
Total Drug Leads 336 1805
Total Device &
Diagnostic Leads
146 724

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

ArQule, Inc. doses the first patient in a Phase I/II clinical trial with ARQ 092 for the treatment of overgrowth diseases driven by genetic alterations of the PI3K/AKT1 pathway:

  • Therapeutic Area: Other
  • Dosage Form: Oral
  • API: Chemical – High potency non-cyto

Get deeper information about the likely upcoming needs of ArQule, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

PharmSource Coverage of ASCO 2017

by Mahdia Hashimy, Research Analyst

Chicago hosted 30,000 American Society of Clinical Oncology (ASCO) conference visitors this weekend, including myself and fellow researcher Scotty Chung-Siu. You may have noticed the uptick in the PharmSource Lead Sheet recently, especially in Phase I & II studies.

In fact, oncology leads hold 46% of this week’s PharmSource Lead Sheet, so be sure to check it out to find more information, including… read on

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on AmpliPhi Biosciences Corporation

AmpliPhi Biosciences, (formerly known as Targeted Genetics Corporation), develops gene-based products for the treatment of acquired and inherited diseases. They raised $9.1 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to fund general corporate purposes, including manufacturing, R&D activities and ongoing clinical trials of its pipeline, which may include… read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on CartiHeal Ltd.

CartiHeal Ltd. is a private company based in Israel that develops cell-free cartilage regeneration technology. They raised $18.3 million in the completion of a venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to fund the IDE clinical trial with its Agili-C implant… read on


PharmSource is attending DIA 2017 in Chicago.

Date: June 18 to June 22
Location: Chicago, IL, USA

For more information click here.

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).